Tratamiento farmacológico de los trastornos de ansiedad

Q4 Medicine

Atencion Primaria Practica Pub Date : 2023-12-19 DOI:10.1016/j.appr.2023.100189

Antonieta Also Fontanet , Natalia Echiburu Salinas , Jessica Pinto Asenjo

{"title":"Tratamiento farmacológico de los trastornos de ansiedad","authors":"Antonieta Also Fontanet , Natalia Echiburu Salinas , Jessica Pinto Asenjo","doi":"10.1016/j.appr.2023.100189","DOIUrl":null,"url":null,"abstract":"<div><p>The main objective of the treatment for anxiety disorders is to relieve symptoms, prevent relapse and avoid sequels. An integral therapeutic approach most be considered (psychosocial, biologic and pharmacologic). The antidepressants and anxiolytics are the mainstay pharmacological treatment. When the prescription is made, the patient must be informed of therapeutic objectives, duration and possible side effects. Age, previous treatment, tolerance, pregnancy and side effects most be considered. In Spain there is a high rate of prescription and consume of antidepressants and anxiolytics: the data of “Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)” support that the consume of antidepressants in Spain has passed from 26.5 DHD (Daily doses per 1000 habitants/Dose per day per 1000 habitants) in the year 2000 to 79.5 DHD in the year 2013; translating and increment of 200%. Regarding the anxiolytics the DHD has increased from 50.88 in 2012 to 58.09 in 2022.</p></div>","PeriodicalId":52231,"journal":{"name":"Atencion Primaria Practica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2605073023000238/pdfft?md5=6ba5152fb3bfa88e91697100d163162f&pid=1-s2.0-S2605073023000238-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atencion Primaria Practica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2605073023000238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The main objective of the treatment for anxiety disorders is to relieve symptoms, prevent relapse and avoid sequels. An integral therapeutic approach most be considered (psychosocial, biologic and pharmacologic). The antidepressants and anxiolytics are the mainstay pharmacological treatment. When the prescription is made, the patient must be informed of therapeutic objectives, duration and possible side effects. Age, previous treatment, tolerance, pregnancy and side effects most be considered. In Spain there is a high rate of prescription and consume of antidepressants and anxiolytics: the data of “Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)” support that the consume of antidepressants in Spain has passed from 26.5 DHD (Daily doses per 1000 habitants/Dose per day per 1000 habitants) in the year 2000 to 79.5 DHD in the year 2013; translating and increment of 200%. Regarding the anxiolytics the DHD has increased from 50.88 in 2012 to 58.09 in 2022.

查看原文本刊更多论文

焦虑症的药物治疗

治疗焦虑症的主要目的是缓解症状、防止复发和避免后遗症。应考虑采取综合治疗方法（社会心理、生物和药物治疗）。抗抑郁剂和抗焦虑药是主要的药物治疗方法。在开处方时，必须告知患者治疗目的、持续时间和可能出现的副作用。此外，还必须考虑患者的年龄、既往治疗情况、耐受性、怀孕情况和副作用。在西班牙，抗抑郁药和抗焦虑药的处方率和使用率都很高："西班牙药品和卫生产品机构（AEMPS）"的数据表明，西班牙抗抑郁药的使用率已从 2000 年的 26.5 DHD（每千人每日剂量/每千人每日剂量）上升到 2013 年的 79.5 DHD，增幅达 200%。抗焦虑药的日剂量从2012年的50.88增至2022年的58.09。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Atencion Primaria Practica Medicine-Family Practice

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

24 days